Susana Correia
Director, Neuromuscular Research Dyne Therapeutics
Susana Correia is a Director of Genetic Medicines Research at Dyne Therapeutics in Waltham, MA where she leads CNS drug discovery focused on the development of treatments for neuromuscular and potential applications of Dyne’s FORCE platform to CNS indications. Prior to joining Dyne, Susana advanced therapies for both neurodegenerative and neuropsychiatric diseases at multiple biotech companies. Her PhD training in molecular neuroscience started at the University of Coimbra in Portugal, her native country and her research career continued at the University of Michigan, Ann Arbor, MI and MIT in Cambridge, MA where she conducted research on the molecular, cellular and neural circuit mechanisms underlying synaptic plasticity, cognition and anxiety-related brain biology.
Seminars
- We have developed a TfR1 mediated delivery platform capable of transporting therapeutic oligonucleotides to both muscle and the CNS
- This delivery platform has translated into clinically meaningful functional improvements in neuromuscular diseases, including DMD and DM1
- In the CNS, our approach achieves broad and homogeneous brain distribution of oligonucleotide payloads, reaching deep brain regions that are inaccessible via intrathecal administration
